Cerus Co. (NASDAQ:CERS – Get Rating) was the recipient of a significant decline in short interest in the month of April. As of April 30th, there was short interest totalling 7,310,000 shares, a decline of 7.9% from the April 15th total of 7,940,000 shares. Based on an average daily volume of 1,390,000 shares, the days-to-cover […]
Cerus (NASDAQ:CERS – Get Rating) was downgraded by stock analysts at StockNews.com from a “hold” rating to a “sell” rating in a research note issued to investors on Monday. A number of other brokerages have also weighed in on CERS. BTIG Research lowered shares of Cerus from a “buy” rating to a “neutral” rating in […]
Salzhauer Michael reduced its holdings in Cerus Co. (NASDAQ:CERS – Get Rating) by 2.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 308,467 shares of the biotechnology company’s stock after selling 9,000 shares during the period. Cerus comprises about […]
Cerus (NASDAQ:CERS – Get Rating) is set to issue its quarterly earnings data after the market closes on Thursday, May 4th. Analysts expect the company to announce earnings of ($0.05) per share for the quarter. Cerus has set its FY 2023 guidance at EPS.Persons that wish to register for the company’s earnings conference call can […]
Cerus (NASDAQ:CERS – Get Rating) and Quipt Home Medical (NASDAQ:QIPT – Get Rating) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, profitability, valuation and dividends. Insider and Institutional Ownership 82.5% of Cerus shares are […]